Ozempic Weight Loss: Expected Results and Individual Factors

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Clinical trials show semaglutide users lose 5–22% of body weight depending on dose and study duration. However, this wide range reflects real individual differences—not everyone loses at the same rate or to the same degree. Understanding what drives these differences is key to realistic planning.

When considering semaglutide or other GLP-1 medications, average trial data tells only part of the story. Your genetics, metabolic markers, adherence capacity, and lifestyle context shape your likely outcome. PlexusDx supports a precision-wellness approach that helps you and your provider have a more informed conversation about what to expect.

Clinical Trial Data: What the Research Actually Shows

The SUSTAIN trials (semaglutide for type 2 diabetes) demonstrated weight reductions ranging from 3–6 kg at lower doses to 10–14 kg at higher doses over 56 weeks. The STEP trials (semaglutide for weight management in non-diabetic individuals) showed more impressive results: users lost 10–15% of baseline body weight at moderate doses and up to 22% at the highest dose.

These trials enrolled carefully screened participants with consistent medication adherence, structured lifestyle support, and regular provider monitoring. Real-world outcomes often differ because not all users maintain the same adherence, dietary discipline, or exercise consistency as trial participants. Understanding your own capacity for these behaviors is crucial for setting realistic expectations.

Variables That Influence Individual Weight Loss Outcomes

Six major factors determine how much weight you might lose on semaglutide: starting body weight, dose and duration of treatment, baseline metabolic health, genetic predisposition to GLP-1 sensitivity, adherence to medication and lifestyle changes, and presence of other metabolic conditions. No two patients experience identical results because each person's combination of these factors is unique.

Factor	Impact on Weight Loss
Dose Level	Higher doses (2.4 mg) typically yield greater weight loss than lower maintenance doses; dose escalation period affects timeline.
Treatment Duration	Weight loss accumulates over 16–68 weeks in trials; continued use may support sustained loss or further reduction.
Baseline BMI	Individuals with higher starting BMI often lose more absolute weight; percentage loss may be similar across BMI ranges.
Lifestyle Adherence	Concurrent dietary changes and physical activity amplify GLP-1 effect; sedentary lifestyle may blunt results.
Genetic Peptide Pathways	Variants in GLP1R, GIPR, FTO, and MC4R genes may influence individual GLP-1 sensitivity and metabolic response.
Metabolic Health Status	Presence of insulin resistance, PCOS, or thyroid dysfunction can modify weight-loss trajectory and require provider oversight.

Why Genetic Context Matters for Realistic Expectations

Genetic variation in GLP-1 receptor sensitivity, FTO (fat mass-related) variants, and melanocortin-4 receptor (MC4R) genes may influence how efficiently your body responds to semaglutide. Someone with a genetic predisposition favoring GLP-1 sensitivity may experience faster, more substantial weight loss than someone with less favorable variants. These are predispositions, not guarantees.

The Precision Peptide Genetic Test identifies key variants (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that may help provide context about your peptide-pathway biology. This information, interpreted with your provider, can help shape realistic timelines and expectations. It should not replace medical evaluation but can support a more informed conversation about individual variation in GLP-1 response.

Safety, Duration, and Who This Approach Applies To

Semaglutide is a prescription medication appropriate for adults with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related health conditions. Common side effects (nausea, vomiting, diarrhea) are typically mild to moderate and often improve with time or dose adjustment. Contraindications include personal/family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, or pregnancy.

Weight loss typically plateaus after 16–24 weeks unless dose is increased or lifestyle changes intensify. Maintaining weight loss requires continued medication use and healthy behaviors; stopping semaglutide often leads to weight regain. Your provider should monitor you regularly for safety and efficacy. Compounded semaglutide from licensed 503A pharmacies offers a more affordable alternative to branded options while maintaining the same active ingredient and requiring equivalent medical oversight.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your individual genetic predispositions in key GLP-1 and metabolic-pathway genes. Understanding whether you carry variants associated with higher or lower GLP-1 receptor sensitivity can inform a conversation with your provider about what weight-loss timeline and magnitude might be realistic for you. This is not a prediction of exact medication response, but rather a biomarker-informed starting point.

The genetic test reveals predispositions in four critical pathways: GLP1R sensitivity, GIPR function, FTO (fat mass regulation), and MC4R signaling. Individuals with favorable variants in GLP1R and GIPR genes may experience more pronounced appetite suppression and faster weight loss. Those with certain FTO or MC4R variants may face metabolic or appetite-control challenges requiring more deliberate lifestyle effort. These insights should be interpreted with a qualified healthcare provider.

When you combine genetic predisposition data with your clinical history, metabolic markers, and lifestyle capacity, you and your provider can set more personalized goals. Rather than aiming for the 22% average from STEP trials, you might reasonably expect 10–15% based on your genetic context and circumstances. This precision-wellness approach supports informed decision-making and sustainable outcomes with compounded semaglutide or other GLP-1 medications.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral starts at from $209/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.